The board of directors of Bud Genius (Symbol: RIGH) yesterday began discussion on filing an S-1 registration for its new subsidiary, Genius Biotech Corporation, to be listed on the OTC:BB, following a full audit.
Company CEO, Angel Stanz, had this to say, “We want to be a respectable publicly traded company. We already provide reliable information to doctors and patients about medical marijuana. By now it is key to set us apart from the rest of the industry as a leader with the highest standards. Aside from laboratory testing and certification, we believe our company may best be represented with a registration of our shares. We have hired an advisory firm to help us determine the value of our new company, to weigh the benefits, and to help us determine if this is going to be a good thing. Such a registration could benefit our shareholders, and help provide a higher level of credibility to quality leaders working with laboratory-grade medical marijuana.
Some have told us that this would be the first registration of a real marijuana industry stock because we are part of the true core of the industry by actually handling and testing marijuana, as opposed to just selling support products to others. I don’t know if that is accurate, but Genius Biotech Corporation will be providing a lot more industry firsts than this in terms of integrity and reliability as our nation moves closer to what could be some major changes. We were one of the first in this space and we will continue to stay at the forefront. There are a lot of fantastic companies out there, and people will be looking at us to be the fair judge of laboratory standards. We applaud the SEC’s crackdown on the marijuana industry. It was needed and we hope by our registration to be an example for other companies to follow.”
Limited information about the new company is available at this time, and more information about the company will be provided in the company’s registration at the time of its completion, or on the company’s website after it has been announced.
About Bud Genius
An early leader in an industry that many are speculating will grow, Bud Genius is one of the first established analytical cannabis laboratories in the United States. Bud Genius was launched to bring vendors together with doctors, patients, and dispensaries that require certified products held to demanding standards. Bud Genius has a vision to expand across the US and abroad serving as the beacon of quality for medical cannabis and adult-use marijuana through the formation of regional laboratories. Certification, data collection, and online reports are the measure by which the company gains.
For more information please visit:
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
Angel Stanz, Chief Executive Officer